Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2000 Jun;92(6):285–294.

Bladder cancer: a review of diagnosis and management.

M C Metts 1, J C Metts 1, S J Milito 1, C R Thomas Jr 1
PMCID: PMC2640522  PMID: 10918764

Abstract

Bladder cancer is the fourth most commonly diagnosed malignancy in men and the eighth most common in women. It represents a spectrum of disease, ranging from superficial, well-differentiated disease, which does not significantly impact survival, to highly malignant tumors for which long term survival may be dismal. Transitional-cell carcinoma, which constitutes the vast majority of bladder cancers in the United States, may develop as carcinoma in situ or as invasive carcinoma. This article focuses on transitional-cell carcinoma with a review of the major aspects of the disease, including the epidemiology, diagnosis and staging, and management (including organ preservation). Therapeutic options are explored, including surgery, radiotherapy, chemotherapy, and combined modality therapy.

Full text

PDF
288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Althausen A. F., Prout G. R., Jr, Daly J. J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976 Nov;116(5):575–580. doi: 10.1016/s0022-5347(17)58916-8. [DOI] [PubMed] [Google Scholar]
  2. Benson R. C., Jr, Tomera K. M., Kelalis P. P. Transitional cell carcinoma of the bladder in children and adolescents. J Urol. 1983 Jul;130(1):54–55. doi: 10.1016/s0022-5347(17)50950-7. [DOI] [PubMed] [Google Scholar]
  3. Blackard C. E., Byar D. P. Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. J Urol. 1972 Dec;108(6):875–878. doi: 10.1016/s0022-5347(17)60895-4. [DOI] [PubMed] [Google Scholar]
  4. Bloom H. J., Hendry W. F., Wallace D. M., Skeet R. G. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol. 1982 Apr;54(2):136–151. doi: 10.1111/j.1464-410x.1982.tb13537.x. [DOI] [PubMed] [Google Scholar]
  5. Cancrini A., De Carli P., Fattahi H., Pompeo V., Cantiani R., Von Heland M. Orthotopic ileal neobladder in female patients after radical cystectomy: 2-year experience. J Urol. 1995 Mar;153(3 Pt 2):956–958. [PubMed] [Google Scholar]
  6. Cookson M. S., Herr H. W., Zhang Z. F., Soloway S., Sogani P. C., Fair W. R. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul;158(1):62–67. doi: 10.1097/00005392-199707000-00017. [DOI] [PubMed] [Google Scholar]
  7. Crawford E. D., Das S., Smith J. A., Jr Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am. 1987 Nov;14(4):781–787. [PubMed] [Google Scholar]
  8. Dunst J., Sauer R., Schrott K. M., Kühn R., Wittekind C., Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):261–266. doi: 10.1016/0360-3016(94)90003-5. [DOI] [PubMed] [Google Scholar]
  9. Esrig D., Elmajian D., Groshen S., Freeman J. A., Stein J. P., Chen S. C., Nichols P. W., Skinner D. G., Jones P. A., Cote R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994 Nov 10;331(19):1259–1264. doi: 10.1056/NEJM199411103311903. [DOI] [PubMed] [Google Scholar]
  10. Farrow G. M., Utz D. C., Rife C. C. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res. 1976 Jul;36(7 Pt 2):2495–2501. [PubMed] [Google Scholar]
  11. Ghoneim M. A., Kock N. G., Lycke G., el-Din A. B. An appliance-free, sphincter-controlled bladder substitute: the urethral Kock pouch. J Urol. 1987 Nov;138(5):1150–1154. doi: 10.1016/s0022-5347(17)43531-2. [DOI] [PubMed] [Google Scholar]
  12. Gospodarowicz M. K., Hawkins N. V., Rawlings G. A., Connolly J. G., Jewett M. A., Thomas G. M., Herman J. G., Garrett P. G., Chua T., Duncan W. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989 Dec;142(6):1448–1454. doi: 10.1016/s0022-5347(17)39122-x. [DOI] [PubMed] [Google Scholar]
  13. Hall R. R., Newling D. W., Ramsden P. D., Richards B., Robinson M. R., Smith P. H. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol. 1984 Dec;56(6):668–672. doi: 10.1111/j.1464-410x.1984.tb06142.x. [DOI] [PubMed] [Google Scholar]
  14. Harker W. G., Meyers F. J., Freiha F. S., Palmer J. M., Shortliffe L. D., Hannigan J. F., McWhirter K. M., Torti F. M. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985 Nov;3(11):1463–1470. doi: 10.1200/JCO.1985.3.11.1463. [DOI] [PubMed] [Google Scholar]
  15. Hartge P., Silverman D., Hoover R., Schairer C., Altman R., Austin D., Cantor K., Child M., Key C., Marrett L. D. Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst. 1987 Jun;78(6):1119–1125. [PubMed] [Google Scholar]
  16. Hautmann R. E., Egghart G., Frohneberg D., Miller K. The ileal neobladder. J Urol. 1988 Jan;139(1):39–42. doi: 10.1016/s0022-5347(17)42283-x. [DOI] [PubMed] [Google Scholar]
  17. Hautmann R. E., Paiss T., de Petriconi R. The ileal neobladder in women: 9 years of experience with 18 patients. J Urol. 1996 Jan;155(1):76–81. doi: 10.1016/s0022-5347(01)66546-7. [DOI] [PubMed] [Google Scholar]
  18. Heney N. M., Proppe K., Prout G. R., Jr, Griffin P. P., Shipley W. U. Invasive bladder cancer: tumor configuration, lymphatic invasion and survival. J Urol. 1983 Nov;130(5):895–897. doi: 10.1016/s0022-5347(17)51558-x. [DOI] [PubMed] [Google Scholar]
  19. Herr H. W., Schwalb D. M., Zhang Z. F., Sogani P. C., Fair W. R., Whitmore W. F., Jr, Oettgen H. F. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995 Jun;13(6):1404–1408. doi: 10.1200/JCO.1995.13.6.1404. [DOI] [PubMed] [Google Scholar]
  20. Housset M., Maulard C., Chretien Y., Dufour B., Delanian S., Huart J., Colardelle F., Brunel P., Baillet F. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993 Nov;11(11):2150–2157. doi: 10.1200/JCO.1993.11.11.2150. [DOI] [PubMed] [Google Scholar]
  21. Jenkins B. J., Caulfield M. J., Fowler C. G., Badenoch D. F., Tiptaft R. C., Paris A. M., Hope-Stone H. F., Oliver R. T., Blandy J. P. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol. 1988 Oct;62(4):343–346. doi: 10.1111/j.1464-410x.1988.tb04362.x. [DOI] [PubMed] [Google Scholar]
  22. Kaufman D. S., Shipley W. U., Griffin P. P., Heney N. M., Althausen A. F., Efird J. T. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993 Nov 4;329(19):1377–1382. doi: 10.1056/NEJM199311043291903. [DOI] [PubMed] [Google Scholar]
  23. Klän R., Loy V., Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991 Aug;146(2):316–318. doi: 10.1016/s0022-5347(17)37779-0. [DOI] [PubMed] [Google Scholar]
  24. Lamm D. L., Blumenstein B. A., Crawford E. D., Montie J. E., Scardino P., Grossman H. B., Stanisic T. H., Smith J. A., Jr, Sullivan J., Sarosdy M. F. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205–1209. doi: 10.1056/NEJM199110243251703. [DOI] [PubMed] [Google Scholar]
  25. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1. doi: 10.3322/canjclin.49.1.8. [DOI] [PubMed] [Google Scholar]
  26. Logothetis C. J., Samuels M. L., Ogden S., Dexeus F. H., Swanson D., Johnson D. E., von Eschenbach A. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol. 1985 Sep;134(3):460–464. doi: 10.1016/s0022-5347(17)47240-5. [DOI] [PubMed] [Google Scholar]
  27. López-Abente G., González C. A., Errezola M., Escolar A., Izarzugaza I., Nebot M., Riboli E. Tobacco smoke inhalation pattern, tobacco type, and bladder cancer in Spain. Am J Epidemiol. 1991 Oct 15;134(8):830–839. doi: 10.1093/oxfordjournals.aje.a116158. [DOI] [PubMed] [Google Scholar]
  28. Mameghan H., Fisher R., Mameghan J., Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):247–254. doi: 10.1016/0360-3016(94)E0135-7. [DOI] [PubMed] [Google Scholar]
  29. Mathur V. K., Krahn H. P., Ramsey E. W. Total cystectomy for bladder cancer. J Urol. 1981 Jun;125(6):784–786. doi: 10.1016/s0022-5347(17)55202-7. [DOI] [PubMed] [Google Scholar]
  30. Miller L. S. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer. 1977 Feb;39(2 Suppl):973–980. doi: 10.1002/1097-0142(197702)39:2+<973::aid-cncr2820390737>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  31. Montie J. E., Straffon R. A., Stewart B. H. Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol. 1984 Mar;131(3):477–482. doi: 10.1016/s0022-5347(17)50458-9. [DOI] [PubMed] [Google Scholar]
  32. Pagano F., Bassi P., Galetti T. P., Meneghini A., Milani C., Artibani W., Garbeglio A. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol. 1991 Jan;145(1):45–50. doi: 10.1016/s0022-5347(17)38244-7. [DOI] [PubMed] [Google Scholar]
  33. Rintala E., Hannisdahl E., Fosså S. D., Hellsten S., Sander S. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol. 1993;27(3):355–362. doi: 10.3109/00365599309180447. [DOI] [PubMed] [Google Scholar]
  34. Scher H. I., Yagoda A., Herr H. W., Sternberg C. N., Bosl G., Morse M. J., Sogani P. C., Watson R. C., Dershaw D. D., Reuter V. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol. 1988 Mar;139(3):470–474. doi: 10.1016/s0022-5347(17)42495-5. [DOI] [PubMed] [Google Scholar]
  35. Sell A., Jakobsen A., Nerstrøm B., Sørensen B. L., Steven K., Barlebo H. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl. 1991;138:193–201. [PubMed] [Google Scholar]
  36. Shearer R. J., Chilvers C. F., Bloom H. J., Bliss J. M., Horwich A., Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol. 1988 Dec;62(6):558–564. doi: 10.1111/j.1464-410x.1988.tb04426.x. [DOI] [PubMed] [Google Scholar]
  37. Shiao Y. H., Chen V. W., Scheer W. D., Wu X. C., Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995 Apr 1;55(7):1485–1490. [PubMed] [Google Scholar]
  38. Shipley W. U., Kaufman D. S., Heney N. M., Althausen A. F., Zietman A. L. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 1999 Aug;162(2):445–451. [PubMed] [Google Scholar]
  39. Shipley W. U., Winter K. A., Kaufman D. S., Lee W. R., Heney N. M., Tester W. R., Donnelly B. J., Venner P. M., Perez C. A., Murray K. J. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998 Nov;16(11):3576–3583. doi: 10.1200/JCO.1998.16.11.3576. [DOI] [PubMed] [Google Scholar]
  40. Silverman D. T., Hartge P., Morrison A. S., Devesa S. S. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992 Feb;6(1):1–30. [PubMed] [Google Scholar]
  41. Skinner D. G., Boyd S. D., Lieskovsky G., Bennett C., Hopwood B. Lower urinary tract reconstruction following cystectomy: experience and results in 126 patients using the Kock ileal reservoir with bilateral ureteroileal urethrostomy. J Urol. 1991 Sep;146(3):756–760. doi: 10.1016/s0022-5347(17)37914-4. [DOI] [PubMed] [Google Scholar]
  42. Skinner D. G., Daniels J. R., Russell C. A., Lieskovsky G., Boyd S. D., Nichols P., Kern W., Sakamoto J., Krailo M., Groshen S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991 Mar;145(3):459–467. doi: 10.1016/s0022-5347(17)38368-4. [DOI] [PubMed] [Google Scholar]
  43. Slack N. H., Bross I. D., Prout G. R., Jr Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol. 1977;9(4):393–405. doi: 10.1002/jso.2930090410. [DOI] [PubMed] [Google Scholar]
  44. Smith J. A., Jr, Crawford E. D., Paradelo J. C., Blumenstein B., Herschman B. R., Grossman H. B., Christie D. W. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol. 1997 Mar;157(3):805–808. [PubMed] [Google Scholar]
  45. Splinter T. A., Pavone-Macaluso M., Jacqmin D., Roberts J. T., Carpentier P., de Pauw M., Sylvester R. A European Organization for Research and Treatment of Cancer--Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response. J Urol. 1992 Dec;148(6):1793–1796. doi: 10.1016/s0022-5347(17)37031-3. [DOI] [PubMed] [Google Scholar]
  46. Srougi M., Simon S. D. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup. J Urol. 1994 Mar;151(3):593–597. doi: 10.1016/s0022-5347(17)35024-3. [DOI] [PubMed] [Google Scholar]
  47. Stein J. P., Stenzl A., Grossfeld G. D., Freeman J. A., Esrig D., Boyd S. D., Lieskovsky, Bartsch G., Skinner D. G. The use of orthotopic neobladders in women undergoing cystectomy for pelvic malignancy. World J Urol. 1996;14(1):9–14. doi: 10.1007/BF01836338. [DOI] [PubMed] [Google Scholar]
  48. Stenzl A., Colleselli K., Poisel S., Feichtinger H., Pontasch H., Bartsch G. Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women. J Urol. 1995 Dec;154(6):2044–2049. [PubMed] [Google Scholar]
  49. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Ahmed T., Weiselberg L. R., Geller N., Hollander P. S., Herr H. W., Sogani P. C. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985 Mar;133(3):403–407. doi: 10.1016/s0022-5347(17)48996-8. [DOI] [PubMed] [Google Scholar]
  50. Studer U. E., Ackermann D., Casanova G. A., Zingg E. J. Three years' experience with an ileal low pressure bladder substitute. Br J Urol. 1989 Jan;63(1):43–52. doi: 10.1111/j.1464-410x.1989.tb05122.x. [DOI] [PubMed] [Google Scholar]
  51. Stöckle M., Meyenburg W., Wellek S., Voges G., Gertenbach U., Thüroff J. W., Huber C., Hohenfellner R. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992 Aug;148(2 Pt 1):302–307. doi: 10.1016/s0022-5347(17)36578-3. [DOI] [PubMed] [Google Scholar]
  52. Tester W., Porter A., Asbell S., Coughlin C., Heaney J., Krall J., Martz K., Venner P., Hammond E. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):783–790. doi: 10.1016/0360-3016(93)90306-g. [DOI] [PubMed] [Google Scholar]
  53. Wijkström H., Edsmyr F., Lundh B. The value of preoperative classification according to the TNM system. A critical examination of Category T2 in 96 patients with grade 3 transitional cell bladder carcinoma subjected to preparative irradiation and cystectomy. Eur Urol. 1984;10(2):101–106. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES